Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT00823719 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large-Cell, Diffuse

Interventions

DRUG: ofatumumab + ICE
DRUG: ofatumumab + DHAP

Sponsor

GlaxoSmithKline